OPT - Opthea Ltd Market Cap to Sales Volume

Symbol and logo of brand Opthea Corp (OPT)

Demand for retinal treatment is independent of economic cycles, and this price-to-sales ratio chart on GURU.Markets confirms stable interest, with the metric holding around 5776.30. However, the expansion of clinical sites prior to FDA approval is temporarily increasing unit costs. Meanwhile, sozinibercept creates a unique advantage by improving visual acuity in AMD for Opthea Limited (OPT).

OPT: Opthea Ltd. P/S Multiple 07/04/2022 - 06/28/2025

Opthea Ltd. (OPT) - metric breakdowns and financial figures

- share price and expert price forecast:
Quote Chart opthea.com|OPT - Consensus Target
- market capitalization statistics:
Market Value Opthea Ltd.|OPT - Enterprise Value
- book capitalization information:
Accounting Value of a Share Opthea|OPT - Book Capitalization|Market-to-Book Ratio opthea.com|OPT - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Opthea Limited|OPT - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Opthea Corp|OPT - Company Debts|Debt to Book Capitalization Ratio Opthea Ltd.|OPT - Company Long-Term Debts|Short-Term Debt Volume Opthea|Quick Liquidity Indicator opthea.com
- earnings and valuation multiples information:
OPT - Net Profit|Company Profit Forecast Opthea Limited|OPT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Opthea Ltd|OPT - PEG Multiple|Company Value to EBITDA Opthea Ltd.|OPT - Operating profit EBITDA|Earnings per share for the last 12 months Opthea|OPT - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months opthea.com|OPT - Earnings per share growth in current year|Net earnings per share change forecast for next year Opthea Limited
- issuer revenue and sales details:
OPT - Company Sales|Company Projected Revenue Volume opthea.com|OPT - Price-to-Revenue Ratio|Future Price to Revenue Opthea Ltd.
Fundamental company analysis:opthea.com OPT
Signature product of Opthea Corp

The development of an innovative drug for the treatment of AMD makes Opthea Limited (OPT) dependent on market expectations, which is reflected in the P/S ratio that compares the business's market value with its annual sales volume. By analyzing the dynamics of the market cap-to-revenue ratio, an investor can identify the gap between operational reality and quotes, assessing the extent to which the asset's current price is justified by fundamental growth rates.

Competing companies

ALC: Price-to-Sales Ratio|Bausch + Lomb - Market Cap to Revenue|Market Cap to Sales Volume GKOS (Glaukos Corp)|Apellis Pharmaceuticals Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio BLTE (Belite Bio, Inc)|OCUL: P/S Multiple|Price to Sales harrowinc.com (HROW)|VRDN (Viridian Therapeutics, Inc.) - P/S Multiple|P/S Multiple LENZ Therapeutics Inc|Market Cap to Revenue OCS (Oculis AG)|EYPT (EyePoint Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kodiak Sciences Inc. KOD|Aldeyra Therapeutics Inc. - Price-to-Revenue Ratio|Kala Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient Opus Genetics Inc IRD|okyopharma.com (OKYO) - Price-to-Revenue Ratio|Market Cap to Revenue Adverum Biotechnologies, Inc.|OTLK (Outlook Therapeutics) - P/S Multiple|clearsidebio.com (CLSD) - Price-to-Revenue Coefficient|Market Cap to Revenue NBY (NovaBay Pharmaceuticals)|Market Cap to Sales Volume KPRX|P/S Multiple ALIM (Alimera Sciences, Inc.)|Eyenovia Inc. (EYEN) - Price to Sales|Guardion Health Science - P/S Multiple|OCUP (ocuphire.com) - Market Cap to Revenue Ratio